Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;13(1):12-8.
doi: 10.28092/j.issn.2095-3941.2016.0003.

Changing paradigm of cancer therapy: precision medicine by next-generation sequencing

Affiliations

Changing paradigm of cancer therapy: precision medicine by next-generation sequencing

Yuan Xue et al. Cancer Biol Med. 2016 Mar.

Abstract

Precision medicine aims to identify the right drug, for the right patient, at the right dose, at the right time, which is particularly important in cancer therapy. Problems such as the variability of treatment response and resistance to medication have been long-standing challenges in oncology, especially for development of new medications. Solid tumors, unlike hematologic malignancies or brain tumors, are remarkably diverse in their cellular origins and developmental timing. The ability of next-generation sequencing (NGS) to analyze the comprehensive landscape of genetic alterations brings promises to diseases that have a highly complex and heterogeneous genetic composition such as cancer. Here we provide an overview of how NGS is able to facilitate precision medicine and change the paradigm of cancer therapy, especially for solid tumors, through technical advancements, molecular diagnosis, response monitoring and clinical trials.

Keywords: Precision medicine; cancer therapy; next-generation sequencing; solid tumor.

PubMed Disclaimer

Figures

Figure1
Figure1
How NGS technology enables precision medicine in cancer.

References

    1. Mendoza MC. HIM and the path to personalized medicine. J AHIMA. 2010;81: 38–42; quiz 43. - PubMed
    1. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11: 31–46. doi: 10.1038/nrg2626. - DOI - PubMed
    1. Chen X, Pappo A, Dyer MA. Pediatric solid tumor genomics and developmental pliancy. Oncogene. 2015;34: 5207–15. doi: 10.1038/onc.2014.474. - DOI - PMC - PubMed
    1. Spier I, Drichel D, Kerick M, Kirfel J, Horpaopan S, Laner A, et al. Low-level APC mutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. J Med Genet. 2016;53: 172–9. doi: 10.1136/jmedgenet-2015-103468. - DOI - PubMed
    1. Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, et al. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015;11: e1005637. doi: 10.1371/journal.pgen.1005637. - DOI - PMC - PubMed

LinkOut - more resources